EU-sovereign · DNA re-analysis · made in Finland

Your genome doesn't change.
The science does.

Aimosti re-analyses a DNA file you already own, a sequenced genome or a 23andMe-style chip export, against current clinical and research databases. When the evidence shifts, we re-read your file and flag what changed.

From €19 for a genotyping-array file (23andMe, AncestryDNA, MyHeritage, FamilyTreeDNA, LivingDNA), or €39 for whole-genome. One-time, yours to keep.

Check your file, free, in your browser Get your report · €39 See a sample report Learn what your genome can tell you

We keep your report current. Own every report forever. €29/yr keeps it updating. Stop anytime and you keep the last one. Never rented back to you.

Your data stays in Finland. Encrypted in transit, never sold, deleted on demand.

aimosti · report.pdf

Pharmacogenomics

Evidence ★★★★Effect Marked

Clopidogrel response

CYP2C19

10:94,781,859 · CYP2C19 *2/*2 · poor metaboliser. Restating CPIC: clopidogrel may be less effective, one to discuss with a prescriber. Never a diagnosis.

Clinical finding

Evidence ★★★★Effect Actionable

Hereditary haemochromatosis

HFE

6:26,092,913 · C282Y homozygous · the common iron-overload genotype. Highly manageable once known. Restating ClinVar, to confirm with a clinician and a validated test. Never a diagnosis.

Carrier status

Evidence ★★★★Effect Carrier

Cystic fibrosis carrier

CFTR

7:117,559,592 · F508del · heterozygous. One copy is typically unaffected; it matters for family planning. We also name the conditions a file cannot rule out.

Deep Read · star allele

Evidence ★★★★★Effect Marked

Codeine & tramadol

CYP2D6

CYP2D6 *1/*2 · normal metaboliser, resolved from your aligned reads, the star-allele a standard VCF cannot reliably call. Restating CPIC.

Trait & wellness

Evidence ★★★Effect Modest

Caffeine metabolism

CYP1A2

15:74,749,576 · rs762551 A/A · associated with faster caffeine clearance. A benign, well-replicated, genome-wide-significant trait. No folklore.

Frontier · exploratory

Evidence ★★ MixedEffect Context

COMT “warrior / worrier”

rs4680

22:19,963,748 · A/A → slower dopamine clearance. A U-shaped, context-dependent association, not a label. Below the credibility firewall. Not medical.

Restated from ClinVar·ACMG SF·CPIC·GWAS Catalog·gnomAD·PhyloTree

Your report is an app. This is it.

Every panel below is the real report engine over a made-up genome, the same one the sample walkthrough uses. Nothing here is a picture of the product.

aimosti · app · sample persona

Overview Your files Medications 8 Health risks Carrier status Partner view Traits Ancestry Explore Report & PDF Variant Explorer Genome Watch

Overview

what matters, then everything else

Things to look at

Genes affecting medications

Carrier findings

✓

Report up to date

Your genome, by area

Medications29 genes

ABCG2 · Poor Function

13 genes affect your medications · Deep Read active

well-supportedOpen →

Health risks18

4 findings

Monogenic findings, risk factors, single-gene results, polygenic scores

establishedOpen →

Carrier status3

Carrier · ATP7B

Matters for family planning, not your own health

well-supportedOpen →

Traits26/26

Blood type, caffeine, lactase, and more

Lifestyle-adjacent, lower stakes

emergingOpen →

Ancestrymt · Y

Maternal + paternal lineage

Deep lineage, composition, and archaic ancestry

establishedOpen →

Explore58

Frontier & Fringe, speculative

Walled off on purpose. Fun, not medicine.

emergingOpen →

+ Upload a new file · Re-run your report on new data

Medications

Deep Read ✓ 29 genes

How your genes can affect the way your body handles specific drugs.

Print-for-your-doctor hand-off A one-page clinician summary, available in your own report.

Action needed Use caution Standard Not called

Drugs worth flagging to a prescriber · 39

rosuvastatin Action needed

Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects CPIC's combined ABCG2+SLCO1B1 guidance, shown assuming SLCO1B1 is typical.

ABCG2 Poor Function

desflurane · enflurane · halothane · isoflurane · methoxyflurane · sevoflurane · succinylcholine Action needed

Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine CPIC's combined CACNA1S+RYR1 guidance, shown assuming RYR1 is typical.

CACNA1S Malignant Hyperthermia Susceptibility

efavirenz Action needed

Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation

CYP2B6 Poor Metabolizer

sertraline Action needed

Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects. CPIC's combined CYP2B6+CYP2C19 guidance, shown assuming CYP2C19 is typical.

CYP2B6 Poor Metabolizer

Codeine / tramadol Action needed

Rapid conversion can produce unsafe active-opioid levels.

CYP2D6 Ultrarapid Metabolizer

Tamoxifen Action needed

Increased endoxifen formation.

CYP2D6 Ultrarapid Metabolizer

aminosalicylic acid · aspirin · chloramphenicol · chloroquine · ciprofloxacin · dimercaprol · doxorubicin · furazolidone · glyburide · hydroxychloroquine · mafenide · nalidixic acid · norfloxacin · ofloxacin · phenazopyridine · quinine · sulfadiazine · sulfadimidine · sulfamethoxazole / trimethoprim · sulfanilamide · sulfasalazine · sulfisoxazole · tolbutamide · vitamin c · vitamin k Action needed

Low-to-no risk of acute hemolytic anemia

G6PD Deficient

dapsone · methylene blue · pegloticase · rasburicase · tafenoquine · toluidine blue Action needed

High risk of acute hemolytic anemia

G6PD Deficient

nitrofurantoin Action needed

Medium risk of acute hemolytic anemia

G6PD Deficient

primaquine Action needed

High risk of acute hemolytic anemia with standard (or higher than standard) anti-relapse dosages for Plasmodium vivax or Plasmodium ovale of 0.25-0.5 mg/kg daily for 14 days

G6PD Deficient

hydralazine Action needed

Predicted to have increased hydralazine plasma concentrations compared to NAT2 rapid and intermediate metabolizers, which may lead to both increased efficacy and adverse effects, including drug-induced systemic lupus erythematosus.

NAT2 Poor Metabolizer

atorvastatin Action needed

Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.

SLCO1B1 Poor Function

fluvastatin Action needed

Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg. CPIC's combined SLCO1B1+CYP2C9 guidance, shown assuming CYP2C9 is typical.

SLCO1B1 Poor Function

lovastatin Action needed

Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk

SLCO1B1 Poor Function

pitavastatin Action needed

Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.

SLCO1B1 Poor Function

pravastatin Action needed

Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.

SLCO1B1 Poor Function

rosuvastatin Action needed

Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg. CPIC's combined SLCO1B1+ABCG2 guidance, shown assuming ABCG2 is typical.

SLCO1B1 Poor Function

simvastatin Action needed

Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk

SLCO1B1 Poor Function

amitriptyline Use caution

Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects CPIC's combined CYP2C19+CYP2D6 guidance, shown assuming CYP2D6 is typical.

CYP2C19 Rapid Metabolizer

citalopram · escitalopram Use caution

Increase in metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.

CYP2C19 Rapid Metabolizer

clomipramine Use caution

CYP2C19 Rapid Metabolizer

clopidogrel Use caution

Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk

CYP2C19 Rapid Metabolizer

dexlansoprazole Use caution

Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure

CYP2C19 Rapid Metabolizer

doxepin Use caution

CYP2C19 Rapid Metabolizer

imipramine Use caution

CYP2C19 Rapid Metabolizer

lansoprazole · omeprazole · pantoprazole Use caution

Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure

CYP2C19 Rapid Metabolizer

sertraline Use caution

Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. CPIC's combined CYP2C19+CYP2B6 guidance, shown assuming CYP2B6 is typical.

CYP2C19 Rapid Metabolizer

trimipramine Use caution

CYP2C19 Rapid Metabolizer

voriconazole Use caution

In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing

CYP2C19 Rapid Metabolizer

Warfarin Use caution

Slower clearance generally predicts a lower stable dose and a higher early-bleeding risk.

CYP2C9 Intermediate metabolizer

NSAIDs (e.g. celecoxib, ibuprofen) Use caution

Higher exposure to CYP2C9-cleared NSAIDs is possible.

CYP2C9 Intermediate metabolizer

capecitabine · fluorouracil Use caution

Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs

DPYD Intermediate Metabolizer

azathioprine Use caution

Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. CPIC's combined NUDT15+TPMT guidance, shown assuming TPMT is typical.

NUDT15 Intermediate Metabolizer

mercaptopurine Use caution

Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. CPIC's combined NUDT15+TPMT guidance, shown assuming TPMT is typical.

NUDT15 Intermediate Metabolizer

thioguanine Use caution

Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. CPIC's combined NUDT15+TPMT guidance, shown assuming TPMT is typical.

NUDT15 Intermediate Metabolizer

azathioprine Use caution

TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs. CPIC's combined TPMT+NUDT15 guidance, shown assuming NUDT15 is typical.

TPMT Intermediate Metabolizer

mercaptopurine Use caution

TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs when receiving standard dose. CPIC's combined TPMT+NUDT15 guidance, shown assuming NUDT15 is typical.

TPMT Intermediate Metabolizer

thioguanine Use caution

TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites compared to TPMT NMs. CPIC's combined TPMT+NUDT15 guidance, shown assuming NUDT15 is typical.

TPMT Intermediate Metabolizer

atazanavir Use caution

Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.

UGT1A1 Intermediate Metabolizer

The 29-gene panel · 29 called · 0 low-coverage

ABCB1—

rs1045642 (T)/rs1045642 (T)

Standard

ABCG2Poor Function

rs2231142 variant (T)/rs2231142 variant (T)

Action needed

ALDH2—

*1/*2

Standard

BCHE—

Reference/Atypical (rs1799807)

Standard

CACNA1SMalignant Hyperthermia Susceptibility

Reference/c.3257G>A

Action needed

CYP1A2—

*1F/*1F

Standard

CYP2B6Poor Metabolizer

*12/*12

Action needed

CYP2C19Rapid Metabolizer

*1/*17

Use caution

CYP2C8—

*1/*3

Standard

CYP2C9Intermediate metabolizer

*1/*2

Use caution

CYP2C (rs12777823)—

Reference/rs12777823 (A)

Standard

CYP2D6Ultrarapid Metabolizer

*1x2/*1

Action needed

CYP3A4—

*1/*22

Standard

CYP3A5Normal Metabolizer

*1/*1

Standard

CYP4F2—

*1/*3

Standard

DPYDIntermediate Metabolizer

Reference/c.1024G>A

Use caution

F2—

Reference/c.*97G>A

Standard

F5—

Reference/Leiden

Standard

G6PDDeficient

202G>A_376A>G_1264C>G/A- 202A_376G

Action needed

GRIK4—

Reference/rs1954787 (C)

Standard

IFNL3—

rs12979860 (C)/rs12979860 (T)

Standard

MTHFR—

rs1801133 (T)/rs1801133 (T)

Standard

NAT2Poor Metabolizer

*14/*14

Action needed

NFIB—

Reference/rs28379954 (C)

Standard

NUDT15Intermediate Metabolizer

*1/*10

Use caution

SLCO1B1Poor Function

*15/*15

Action needed

TPMTIntermediate Metabolizer

*1/*10

Use caution

UGT1A1Intermediate Metabolizer

*1/*27

Use caution

VKORC1—

Reference/rs9923231 (A)

Standard

Details

ABCG2 rs2231142 variant (T)/rs2231142 variant (T) Poor Function

ABCG2: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: rs2231142 variant (T) · rs2231142 variant (T)

In plain terms: Little to no typical activity, which can substantially change how affected medicines behave at a standard dose. A prescriber may adjust the choice or dose.

rosuvastatin

Per CPIC (A): "Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."

CPIC CPIC snapshot 2026-06-13 · CPIC: ABCG2 (allele functionality, diplotype-phenotype, drug guidance)

CACNA1S Reference/c.3257G>A Malignant Hyperthermia Susceptibility 100% callable

CACNA1S: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: Reference · c.3257G>A

In plain terms: Associated with malignant hyperthermia, a serious reaction to certain anaesthetics. Make sure any anaesthetist knows before surgery.

desflurane · enflurane · halothane · isoflurane · methoxyflurane · sevoflurane · succinylcholine

Per CPIC (A): "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."

CPIC CPIC snapshot 2026-06-13 · CPIC: CACNA1S (allele functionality, diplotype-phenotype, drug guidance)

CYP2B6 *12/*12 Poor Metabolizer

CYP2B6: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *12 · *12

In plain terms: This enzyme works slowly, so affected medicines can build up at a standard dose, sometimes meaning stronger effects or more side-effects. A prescriber may choose a lower dose or a different medicine.

efavirenz

Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation

Per CPIC (A): "Consider initiating efavirenz with decreased dose of 400 or 200 mg/day"

sertraline

Per CPIC (B): "Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6."

CPIC CPIC snapshot 2026-06-13 · CPIC: CYP2B6 (allele functionality, diplotype-phenotype, drug guidance)

CYP2C19 *1/*17 Rapid Metabolizer 87% callable

CYP2C19: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *17

In plain terms: This enzyme works faster than typical, so affected medicines may be cleared more quickly than a standard dose assumes, worth a prescriber's awareness.

amitriptyline

Per CPIC (A): "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment."

citalopram · escitalopram

Increase in metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.

Per CPIC (A): "Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19."

clomipramine

Per CPIC (B): "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."

clopidogrel

Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk

Per CPIC (A): "If considering clopidogrel, use at standard dose (75 mg/day)"

dexlansoprazole

Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure

Per CPIC (B): "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy."

doxepin

Per CPIC (B): "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment."

imipramine

Per CPIC (B): "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."

lansoprazole · omeprazole · pantoprazole

Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure

Per CPIC (A): "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy."

sertraline

Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. CPIC's combined CYP2C19+CYP2B6 guidance, shown assuming CYP2B6 is typical.

Per CPIC (A): "Initiate therapy with recommended starting dose."

trimipramine

Per CPIC (B): "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."

voriconazole

In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing

Per CPIC (A): "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole."

CPIC CPIC snapshot 2026-06-13 · CPIC: CYP2C19 (allele functionality, diplotype-phenotype, drug guidance)

CYP2C9 *1/*2 Intermediate metabolizer 93% callable

A liver enzyme that clears warfarin, several NSAIDs and phenytoin. Reduced-function variants slow that clearance.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *2
Activity score: 1.5

In plain terms: This enzyme works somewhat slower than typical, so affected medicines can build up a little at a standard dose, worth a prescriber's awareness.

Warfarin

Slower clearance generally predicts a lower stable dose and a higher early-bleeding risk.

CPIC: the genotype-guided warfarin algorithm (CYP2C9 + VKORC1 + clinical factors) applies; reduced function typically lowers the predicted dose.

NSAIDs (e.g. celecoxib, ibuprofen)

Higher exposure to CYP2C9-cleared NSAIDs is possible.

CPIC: the guideline discusses starting at the lowest effective dose for affected NSAIDs and titrating to response.

CPIC CPIC (CYP2C9 activity score; warfarin 2017) · CPIC: warfarin, CYP2C9 & VKORC1 · PharmVar: CYP2C9 (nomenclature)

CYP2D6 *1x2/*1 Ultrarapid Metabolizer

The most important drug-metabolising enzyme: it activates or clears codeine, tramadol, tamoxifen and roughly a quarter of common medications. Copy-number and paralog structure make it readable only from aligned reads.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *1 · *1
Activity score: 3.0

In plain terms: This enzyme works much faster than typical: some medicines are cleared quickly (a standard dose may be too low), and for a few 'prodrugs' (such as codeine) the body can make too much active drug. A prescriber should be aware.

Codeine / tramadol

Rapid conversion can produce unsafe active-opioid levels.

CPIC: the guideline suggests avoiding codeine/tramadol and using an analgesic not metabolised by CYP2D6.

Tamoxifen

Increased endoxifen formation.

CPIC: standard use per label.

CPIC CPIC (CYP2D6 allele functionality + activity score, 2021) · CPIC: CYP2D6 allele functionality & activity score · PharmVar: CYP2D6 (nomenclature)

DPYD Reference/c.1024G>A Intermediate Metabolizer 85% callable

DPYD: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: Reference · c.1024G>A

In plain terms: This enzyme works somewhat slower than typical, so affected medicines can build up a little at a standard dose, worth a prescriber's awareness.

capecitabine · fluorouracil

Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs

Per CPIC (A): "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available)."

CPIC CPIC snapshot 2026-06-13 · CPIC: DPYD (allele functionality, diplotype-phenotype, drug guidance)

G6PD 202G>A_376A>G_1264C>G/A- 202A_376G Deficient 97% callable

G6PD: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: 202G>A_376A>G_1264C>G · A- 202A_376G

In plain terms: Reduced G6PD activity, which raises the risk of red-blood-cell breakdown (haemolysis) with certain medicines and foods. Important to flag to a prescriber before those exposures.

aminosalicylic acid · aspirin · chloramphenicol · chloroquine · ciprofloxacin · dimercaprol · doxorubicin · furazolidone · glyburide · hydroxychloroquine · mafenide · nalidixic acid · norfloxacin · ofloxacin · phenazopyridine · quinine · sulfadiazine · sulfadimidine · sulfamethoxazole / trimethoprim · sulfanilamide · sulfasalazine · sulfisoxazole · tolbutamide · vitamin c · vitamin k

Low-to-no risk of acute hemolytic anemia

Per CPIC (C): "No reason to avoid based on G6PD status at standard doses"

dapsone · methylene blue · pegloticase · rasburicase · tafenoquine · toluidine blue

High risk of acute hemolytic anemia

Per CPIC (A): "Avoid use"

nitrofurantoin

Medium risk of acute hemolytic anemia

Per CPIC (A): "Use at standard doses with caution and with close monitoring for anemia"

primaquine

High risk of acute hemolytic anemia with standard (or higher than standard) anti-relapse dosages for Plasmodium vivax or Plasmodium ovale of 0.25-0.5 mg/kg daily for 14 days

Per CPIC (A): "Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis."

CPIC CPIC snapshot 2026-06-13 · CPIC: G6PD (allele functionality, diplotype-phenotype, drug guidance)

NAT2 *14/*14 Poor Metabolizer

NAT2: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *14 · *14

hydralazine

Per CPIC (A): "Initiate therapy at a total daily dose of 40 to 75 mg. Carefully titrate dose upward to clinical effect or guideline-recommended dose; use caution with total daily hydralazine doses of 200 mg or more."

CPIC CPIC snapshot 2026-06-13 · CPIC: NAT2 (allele functionality, diplotype-phenotype, drug guidance)

NUDT15 *1/*10 Intermediate Metabolizer 97% callable

NUDT15: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *10

In plain terms: This enzyme works somewhat slower than typical, so affected medicines can build up a little at a standard dose, worth a prescriber's awareness.

azathioprine

Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. CPIC's combined NUDT15+TPMT guidance, shown assuming TPMT is typical.

Per CPIC (A): "Initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment."

mercaptopurine

Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. CPIC's combined NUDT15+TPMT guidance, shown assuming TPMT is typical.

Per CPIC (A): "Initiate therapy with decreased starting doses (30-80% of standard starting dose) if starting dose is ≥75 mg/m2/day (for malignancy) or ≥1.5 mg/kg/day (for nonmalignancy). If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust mercaptopurine doses based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment. If myelosuppression occurs, and the patient is on combination therapy, emphasis should be on reducing mercaptopurine over other agents."

thioguanine

Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. CPIC's combined NUDT15+TPMT guidance, shown assuming TPMT is typical.

Per CPIC (A): "Initiate therapy with decreased starting doses (30-80% of standard starting dose) if standard starting dose is ≥40 mg/m2/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of thioguanine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment. If myelosuppression occurs, and the patient is on combination therapy, emphasis should be on reducing thioguanine over other agents."

CPIC CPIC snapshot 2026-06-13 · CPIC: NUDT15 (allele functionality, diplotype-phenotype, drug guidance)

SLCO1B1 *15/*15 Poor Function 85% callable

SLCO1B1: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *15 · *15

In plain terms: Little to no typical activity, which can substantially change how affected medicines behave at a standard dose. A prescriber may adjust the choice or dose.

atorvastatin

Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.

Per CPIC (A): "Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."

fluvastatin

Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg. CPIC's combined SLCO1B1+CYP2C9 guidance, shown assuming CYP2C9 is typical.

Per CPIC (A): "Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day."

lovastatin

Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk

Per CPIC (A): "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins)."

pitavastatin

Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.

Per CPIC (A): "Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391)."

pravastatin

Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.

Per CPIC (A): "Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of of [sic] PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg."

rosuvastatin

Per CPIC (A): "Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."

simvastatin

Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk

Per CPIC (A): "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins)."

CPIC CPIC snapshot 2026-06-13 · CPIC: SLCO1B1 (allele functionality, diplotype-phenotype, drug guidance)

TPMT *1/*10 Intermediate Metabolizer

TPMT: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *10

In plain terms: This enzyme works somewhat slower than typical, so affected medicines can build up a little at a standard dose, worth a prescriber's awareness.

azathioprine

mercaptopurine

thioguanine

TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites compared to TPMT NMs. CPIC's combined TPMT+NUDT15 guidance, shown assuming NUDT15 is typical.

CPIC CPIC snapshot 2026-06-13 · CPIC: TPMT (allele functionality, diplotype-phenotype, drug guidance)

UGT1A1 *1/*27 Intermediate Metabolizer

UGT1A1: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *27

In plain terms: This enzyme works somewhat slower than typical, so affected medicines can build up a little at a standard dose, worth a prescriber's awareness.

atazanavir

Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.

Per CPIC (A): "There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice)."

CPIC CPIC snapshot 2026-06-13 · CPIC: UGT1A1 (allele functionality, diplotype-phenotype, drug guidance)

CYP3A5 *1/*1 Normal Metabolizer

CYP3A5: CPIC pharmacogenomic guidance, restated. Phenotype is keyed by the called diplotype; drug guidance is CPIC's, quoted and attributed.

from your aligned reads · PyPGx 0.26.0

Your alleles: *1 · *1

In plain terms: Typical activity for this enzyme: standard prescribing assumptions usually apply for the medicines below.

tacrolimus

Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations.

Per CPIC (A): "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments."

CPIC CPIC snapshot 2026-06-13 · CPIC: CYP3A5 (allele functionality, diplotype-phenotype, drug guidance)

What every panel sits on: 1,042 panel regions of GRCh38 · ClinVar 2026-07 lists 482,198 classified variants

Walk through the sample report Check your file, free

Nothing in your report is our opinion.

What Aimosti does

Re-analyses variant data you already own (a chip export or a whole genome)
Restates ClinVar, ACMG SF, CPIC, GWAS Catalog & PhyloTree, pinned to a version
Shows evidence and effect on two separate axes, never one score
Names the gaps: what a variant file cannot tell you
Re-runs as the databases improve (subscription)

What Aimosti never does

Take a sample, sequence, test, or diagnose
Invent a gene or variant association on our own authority
Collapse weak evidence into a confident-looking number
Sell, share, or mine your data
Report MTHFR or APOE as a clinical finding (we explain why)

Modules

Everything our panels read from a variant file.

Each module is anchored to an authoritative, version-pinned source. The speculative modules are walled off from the clinical ones, so curiosity never wears the authority of settled science.

ClinVar / ACMG SF v3.3

Clinical findings

Pathogenic / likely-pathogenic variants in an established actionable-gene panel, framed as personal risk, never a verdict.

ACMG Tier 3 + ACOG carrier panel

Carrier status

A recessive-lens look at carrier variants in your file, for family planning, with the un-callable conditions named.

CPIC guidelines

Pharmacogenomics

How your genotype may affect specific medicines, restating CPIC, to discuss with a prescriber.

GWAS Catalog

Traits

Benign, well-replicated, genome-wide-significant traits that clear a strict evidence gate. No SNPedia folklore.

PhyloTree

Ancestry · maternal & paternal

Your deep maternal and paternal lines as global haplogroups, one thread of your tree, never a "percent ancestry" figure.

below the firewalllabelled exploratory, never clinical

Expanded · exploratoryEmerging research

Frontier

Dozens of readings from the interesting edge of the science: alcohol-flush and caffeine metabolism, the natural short-sleeper genes, longevity curios, and the over-hyped classics we keep in to set the record straight (the “warrior gene”, the serotonin-transporter “depression gene”). Each one is labelled by how much it weighs.

Just for funSpeculative · curiosity only

The Fringe

The playful gene-quirks people love to look up (why coriander can taste of soap, red hair, spicy-food tolerance, even the genetics of rage at chewing sounds), labelled, bluntly, as for curiosity only.

See every gene, condition & trait we examine, by name →

Alcohol flush, caffeine, the short-sleeper genes.

Everyone else either hides the speculative stuff or sells it as gospel. We show dozens of the variants you actually want to see, each wearing a blunt evidence tier, from replicated down to contested.

How Frontier is gated →

12:111,803,962 · rs671

Established mechanism

ALDH2: the alcohol flush

Your genotype · G/A → Reduced clearance, flush-prone

One variant copy already cripples most of the enzyme that clears acetaldehyde, so it builds up after a drink: the flushing, the queasiness, the racing heart. How strongly you feel it varies with the person and the drink. Not medical.

re-analysis · what changed

＋ NEW ClinVar reclassified a variant in your file to Likely pathogenic.

~ UPDATED A Frontier association gained a replication cohort.

· STABLE Everything else unchanged since your last report.

The report you bought, kept current.

Databases improve every month. Keep just your small normalised variant file and its ancestry marker extract with us, never raw reads, and we silently re-match them as the literature moves, then tell you plainly what changed. Withdraw any time; your last report is always yours.

≈ €29 / year · raw reads never retained

Your most personal data, governed like it matters.

EU ONLYStored and processed in FinlandStored in servers in Helsinki. Your genome never leaves the EU.
ART. 9Explicit, revocable consentGenetic data is special-category under GDPR. One explicit consent processes your file and produces your report; research and marketing stay separate and optional, every choice withdrawable, auditable, and versioned.
CRYPTOEncrypted, never soldEncrypted in transit. We don't sell, share, or mine your data, ever.
DELETEDeleted on demandRaw reads are purged after analysis. Subscribers keep a small normalised variant file and its ancestry marker extract, and only if they ask us to. Delete everything with one request.

Security & your data →

Pay once. The report is yours, and you can keep it current if you choose.

Pick where to start. Every report is a one-time purchase you own forever. To keep it current as the science moves, add the re-analysis subscription for €29/yr. Compare plans →

Genotyping chip

Chip report

€19 one-time

For 23andMe, AncestryDNA, MyHeritage, FamilyTreeDNA, LivingDNA and similar genotyping-array exports: everything your chip can call, fully attributed. Carrier status and the full clinical panel need whole-genome data. MyHeritage kits sold since October 2025 may be sequenced rather than typed on an array, so check which file you have.

Clinical findings your array covers
Pharmacogenomics for the genes your chip typed and resolved
Traits, ancestry & the Frontier module
Plain-language explainers & PDF

See the chip report

Grow into it: upgrade to the full WGS report for €20 whenever you’re ready.

Most complete report

Full report (WGS)

€39 one-time

Every module over your whole-genome file: the deepest read of the genome you already own.

Clinical, carrier, PGx, traits, ancestry
Frontier exploratory module
Plain-language explainers & PDF
Pinned, attributed sources

Get your report · €39

The full clinical-findings panel and carrier status live here. A chip file cannot give you either.

From your aligned reads

Deep Read

€79 one-time

What only aligned reads (the BAM or CRAM from your provider) can answer: CYP2D6 copy number, a per-gene callability map of exactly what we examined, two deletions called from depth and typed HLA-DQ, on top of the full 29-target pharmacogene panel.

CYP2D6 copy number and star alleles
Per-gene callability, measured
Deletions called from depth; HLA-DQ typed
Reads deleted immediately after

Deep Read pricing

Prepay Deep Read with the WGS bundle to save.

The cheaper option, and what it costs later

Promethease and Genetic Genie read the same public databases we do. The difference is time. They hand you a report frozen on the day you run it, read from the few hundred thousand positions a genotyping chip types. We read your whole genome where you have it, attribute every finding to the guideline it came from, and can re-read your file as those guidelines change. Your report is a one-off purchase and stays yours. Keeping it current as the guidelines move is the optional re-analysis subscription, and you can start or stop that whenever you like.

Named services are described from their public product pages; features change and we don't speak for them. Three years later, that report still says exactly what it said on the day you ran it.

Common questions

Do you sequence my DNA?

No. Aimosti never takes a sample or sequences anything. You bring whole-genome data you already had produced; we re-analyse the variant file.

Is this a medical test or diagnosis?

No. Every finding is a literature match against public databases: information to discuss with a clinician and confirm with a validated gene test. It is never a diagnosis or medical advice.

What files do you accept?

A whole-genome gVCF gives the most complete report: it records which regions your sequencing covered, so "not found" can mean "examined and clear" rather than merely absent. A plain VCF also gives the full report, read as variant-only. Nebula Genomics, Dante Labs, Sequencing.com and the like are good to go. Several of them, Nebula, Gencove and Dante among them, only ship a variant-only VCF; that still gives the full report, so upload what you have. Check which depth you bought, though: a whole-genome product can be sold at 1x or 2x as well as at 30x. A low-pass genome is imputed against a reference panel rather than read directly, which is good for ancestry, traits and pharmacogenomics and cannot carry the clinical-findings and carrier panels, so it is the €19 report rather than the €39 one. Genotyping-array raw data from 23andMe, AncestryDNA, MyHeritage, FamilyTreeDNA or LivingDNA works too, for a lighter report (traits, pharmacogenomics and ancestry); clinical findings and carrier status need a sequenced genome. MyHeritage kits sold since October 2025 are sequenced rather than typed on a chip, and the raw-data export they hand you still works here.

Where does my data live?

Stored in Finland (Helsinki), never leaving the EU, never sold or mined, deleted on demand. Security & your data →

All questions →

The genome you already own has more to say.

One living report, many modules. Read in Finland, attributed to the source, yours to keep.

Get your report · €39

Your genome doesn't change.The science does.

Your report is an app. This is it.

Overview

Medications

rosuvastatin

desflurane · enflurane · halothane · isoflurane · methoxyflurane · sevoflurane · succinylcholine

efavirenz

sertraline

amitriptyline

citalopram · escitalopram

clomipramine

clopidogrel

dexlansoprazole

doxepin

imipramine

lansoprazole · omeprazole · pantoprazole

sertraline

trimipramine

voriconazole

Warfarin

NSAIDs (e.g. celecoxib, ibuprofen)

Codeine / tramadol

Tamoxifen

capecitabine · fluorouracil

dapsone · methylene blue · pegloticase · rasburicase · tafenoquine · toluidine blue

nitrofurantoin

primaquine

hydralazine

azathioprine

mercaptopurine

thioguanine

atorvastatin

fluvastatin

lovastatin

pitavastatin

pravastatin

rosuvastatin

simvastatin

azathioprine

mercaptopurine

thioguanine

atazanavir

tacrolimus

Ancestry

Deep Read

Nothing in your report is our opinion.

What Aimosti does

What Aimosti never does

Everything our panels read from a variant file.

Clinical findings

Carrier status

Pharmacogenomics

Traits

Ancestry · maternal & paternal

Frontier

The Fringe

Alcohol flush, caffeine, the short-sleeper genes.

ALDH2: the alcohol flush

The report you bought, kept current.

Your most personal data, governed like it matters.

Pay once. The report is yours, and you can keep it current if you choose.

Chip report

Full report (WGS)

Deep Read

The cheaper option, and what it costs later

Common questions

The genome you already own has more to say.

Your genome doesn't change.
The science does.